This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
Combination drug strategies gain ground in global immuno-oncology pipeline of PD-1 and PD-L1 clinical trials, new report from Cancer Research Institute reveals.
Cancer Research Institute CEO and Director of Scientific Affairs Dr. Jill O’Donnell-Tormey receives inaugural Tara Withington Public Service Award from the Society for Immunotherapy of Cancer.
International neoantigen initiative Tumor Neoantigen Selection Alliance (TESLA) identifies parameters for cancer vaccine or cell therapy advancement
Immunotherapy drug development pipeline continues significant growth in 2020 despite global pandemic impact.
Cancer Research Institute goes virtual for its Immunotherapy Patient Summit Series, connecting patients and caregivers with leading experts in cancer immunotherapy.
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
This July for Sarcoma Awareness Month, we look at new research, new treatments, and how we’re working toward a future immune to sarcoma.
CRI-Chordoma Foundation CLIP Investigator Dr. Cassian Yee is exploring how to design cell therapies for patients with a rare type of sarcoma.